| Patient number1 | Age of inclusion | RA duration2 | Gender (M, F)† | Seropositive3 | MTX dose4 | PRD dose5 | IFX dose6 | (years) | (years) | Waaler | Anti-CCP | (mg) |
| 101 | 60 | 5 | F | + | + | 10 | 7,5 | 300 | 102 | 45 | 14 | F | + | + | 5 | 2,5 | 300 | 106 | 50 | 22 | M | + | + | 7,5 | 0 | 300 | 107 | 49 | 4 | F | + | + | 7,5 | 5 | 300 | 108 | 60 | 10 | F | + | + | 10 | 2,5 | 200 | 110 | 59 | 6 | F | + | + | 7,5 | 0 | 200 | 111 | 57 | 6 | F | + | + | 15 | 2,5 | 200 | 112 | 57 | 15 | F | − | − | 5 | 7,5 | 400 | 113 | 64 | 5 | F | + | + | 10 | 0 | 200 | 116 | 66 | 1 | F | − | − | 10 | 7,5 | 300 | 121 | 54 | 11 | F | − | − | 2,5 | 7,5 | 200 | 125 | 48 | 6 | M | + | + | 2,5 | 0 | 300 | 126 | 35 | 8 | M | + | − | 15 | 10 | 300 | 127 | 57 | 3 | M | + | + | 20 | 7,5 | 300 | 130 | 68 | 11 | M | + | + | 15 | 0 | 300 | 131 | 71 | 21 | M | + | + | 7,5 | 10 | 300 | 132 | 56 | 3 | F | + | + | 15 | 7,5 | 200 | 133 | 30 | 11 | F | + | + | 10 | 5 | 300 | 134 | 54 | 18 | M | + | + | 10 | 5 | 300 | 135 | 56 | 13 | M | − | − | 15 | 5 | 400 | 136 | 52 | 7 | F | + | + | 7,5 | 5 | 200 | 137 | 21 | 3 | M | − | − | 15 | 5 | 300 | 138 | 56 | 24 | F | + | + | 20 | 5 | 300 | 139 | 59 | 13 | M | + | + | 15 | 10 | 200 | 201 | 58 | 7 | M | + | + | 15 | 5 | 300 | 205 | 61 | 2 | F | − | + | 15 | 0 | 200 | 207 | 62 | 29 | F | + | + | 12,5 | 2,5 | 200 | 215 | 34 | 14 | F | + | + | 15 | 10 | 200 | 218 | 74 | 6 | F | + | + | 20 | 5 | 200 | 223 | 44 | 15 | F | + | + | 15 | 0 | 200 | 233 | 59 | 2 | F | + | + | 7,5 | 0 | 200 | 302 | 64 | 5 | F | − | − | 7,5 | 10 | 200 | 303 | 74 | 21 | F | − | − | 7,5 | 5 | 300 | 304 | 57 | 21 | F | − | + | 7,5 | 0 | 300 | 305 | 57 | 26 | M | − | + | 15 | 0 | 300 | 306 | 36 | 13 | M | + | + | 7,5 | 0 | 300 | 307 | 56 | 18 | M | + | + | 20 | 0 | 300 | 308 | 35 | 13 | F | − | + | 10 | 0 | 300 | 309 | 43 | 21 | M | + | + | 12,5 | 5 | 200 |
|
|
Ref. no.: internal patient number, 1xx: Haugesund, 2xx: Bergen, and 3xx: Førde. 2Estimated duration of rheumatoid arthritis disease prior to infliximab treatment. 3Clinical data before treatment (baseline), +: seropositive, −: seronegative, 4MTX: methotrexate, 5PRD: prednisolone, 6IFX: infliximab, †F: female, and M: male.
|